News | Proton Therapy | May 31, 2018

Continuous arc treatment significantly reduces adverse effects of respiration-induced motion on lung cancer patients

Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer

May 31, 2018 — Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at the recent European Society for Radiotherapy and Oncology (ESTRO) 37 Congress, April 20-24 in Barcelona, Spain.

“Beaumont researchers have invented a new mode of proton therapy for lung cancer,” said Peyman Kabolizadeh, M.D., Ph.D., clinical director, Beaumont Proton Therapy Center in Royal Oak. “A continuous proton arc treatment can significantly reduce the adverse effects of respiration-induced motion on lung cancer treatments. This advancement will also result in a better and lower dose of radiation to adjacent organs.”

Explained Kabolizadeh, “The promising results might lead to interest and future development of the proton arc therapy technique. Beaumont continues to be a center of new treatment development through research.”

Proton therapy is a high-tech alternative to X-ray radiation. A scanning beam of proton radiation with online image guidance offers greater precision to destroy cancerous cells, sparing adjacent healthy tissue with fewer side effects.

Proton therapy uses positively charged atomic particles, traveling up to two-thirds the speed of light, to fight cancer. A cyclotron, or particle accelerator, creates protons from hydrogen molecules. The proton beam is sent to the treatment room through a transport system consisting of magnets, called the beam line, finally arriving in the gantry, a device that rotates around the patient. The beam is directed to the patient through a nozzle that targets the tumor.

While proton therapy is not effective against all cancers, it is effective in treating many solid and localized tumors.

Beaumont’s center is one of just 28 proton therapy centers in the U.S. It is the only operational proton therapy center in Michigan. Beaumont doctors have treated or consulted with patients across Michigan and 11 other states since opening the Proton Therapy Center in 2017.

“Our IBA Proteus One single-room treatment system includes precision technologies,” said Kabolizadeh. “Intensity modulated proton therapy with pencil beam scanning technology and 3-D cone beam CT [computed tomography], can target a tumor within less than a millimeter.”

Pencil beam scanning (PBS) refers to the delivery of protons in a thin beam. Like a pencil, the beam uses back and forth motions to target the treatment area – the shape, size and depth — painting a radiation dose on tumors layer by layer. Compared to X-ray beams, which pass through a patient, proton beams deliver targeted radiation to the tumor and then stop – resulting in no exit dose.

For more information: www.beaumont.org


Related Content

News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Point-of-Care Ultrasound (POCUS)

Jan. 22, 2026 — Qure.ai has received a grant from the Gates Foundation to develop a large open-source multi-modal ...

Time January 23, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
News | Magnetic Resonance Imaging (MRI) | Children's Hospital Los Angeles

Oct. 28, 2025 — Bronchopulmonary dysplasia (BPD) is the most common — and most serious — complication of extreme ...

Time October 31, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | X-Ray

Sept. 8, 2025 — A new clinical case study, presented by Qure.ai and Hacettepe University, Turkey, at the IASLC World ...

Time September 10, 2025
arrow
Subscribe Now